Notable Hit: (ABT:NYSE) On Thursday July 20, 2023 Abbott Laboratories (ABT) posted revenues of $9.98 bn beating the mean analyst estimates of $9.69 bn and in the same direction as Advan's forecasted sales. The revenue decreased 11.36% YoY - in line with Advan's employee foot traffic data decrease of 7.36% YoY including all of its subsidiaries and manufacturing facilities in Q2 2023 fiscal. Advan's footfall data have a correlation of 0.93 on a YoY basis with ABT's top-line revenue over the last 9 quarters.
